Bivalirudin Research

Yadava D, Tripathi M, Rai S, Malviya D, Kumar S, Rao N et al.

During continuous renal replacement therapy (CRRT), regional citrate anticoagulation (RCA) and bivalirudin are appealing alternatives since they provide excellent anticoagulation within the circuit without increasing the risk of bleeding. This study has been done to assess the hemofilter survival...

Du J, Liu H, Liu X, Cao S, Zhang Z, Zhang L et al.

Direct thrombin inhibitors may lead to falsely low fibrinogen results. The interference of bivalirudin on fibrinogen assays has not been thoroughly evaluated. This study investigates the interference of bivalirudin on fibrinogen detection and the potential use of activated carbon to address this ...

Dmitriev AP, Akouris PP, Javidan AP, Draper K, Elzawy G, Ebrahim F et al.

Systemic unfractionated heparin (UFH) is routinely administered as procedural anticoagulation during carotid artery procedures. However, Type I, II, and IV hypersensitivity to heparin can occur amongst patients with carotid artery disease who require carotid endarterectomy (CEA) or carotid artery...

Said K, Kbiri H, El Baraka H, El Fassiki N, Bouchama A, Chouikh C et al.

Perioperative management of immune thrombocytopenic purpura (ITP) in cardiac surgery represents a rare yet formidable clinical challenge driven by immune-mediated platelet dysfunction, obligatory systemic anticoagulation, and the profound hemostatic derangements induced by cardiopulmonary bypass....

Palacios-Castelló C, Fernández-Gordon-Sánchez S, Esteve-Ruiz I, Grande-Trillo A, Sobrino-Márquez JM, Adsuar-Gómez A et al.

Heparin-induced thrombocytopenia (HIT) is a rare but potentially fatal immune-mediated complication of heparin therapy. Its incidence is higher after left ventricular assist device (LVAD) implantation compared with other cardiac procedures. While bivalirudin is the most frequently reported altern...

Joelsons D, Andari LVWBU, Zanella do Amaral Campos PP, Mól CG, Bravim BA, Peek GJ et al.

IntroductionExtracorporeal membrane oxygenation (ECMO) involves the use of a synthetic circuit, which initiates a complex interplay of inflammatory and pro-coagulant responses. This intricate, self-reinforcing process results in a prothrombotic state, predisposing patients to arterial, venous, or...

Leonardi S, Landi A, Zito A, Branca M, Frigoli E, Ando' G et al.

The universal definition of percutaneous coronary intervention (PCI)-related myocardial infarction (MI) has been substantially updated over the years, including an increase in the biomarker threshold (from 3 to 5 times the upper reference limit) and the introduction of ancillary criteria such as ...

Rivera Jiménez KE, Mamani Ticona YM, Gutierrez-Chavez G, Astudillo CO, Calle E, Heredia GAT et al.

Background: Unfractionated heparin (UFH) is the standard anticoagulant during cardiopulmonary bypass (CPB). A clinically relevant subset develops heparin resistance (HR)-failure to reach adequate anticoagulation with usual UFH-raising thrombotic risk and complicating perioperative care. Objective...

Beeman A, Issitt RW, Mathias M, Cohen M, Laurence C, Muthialu N et al.

IntroductionHeparin induced thrombocytopenia (HIT) with in paediatric population is rare and subsequent anticoagulation management is challenging. Bivalirudin is a viable alternative to heparin for anticoagulating paediatric patients with HIT, though clinical data are limited. We describe the suc...

Brijlal AA, Colontonio MM, Nimma SR

Pain management after thoracotomy is particularly complex in lung transplant recipients on extracorporeal membrane oxygenation (ECMO), where anticoagulation significantly limits available treatment options. Coagulopathy constitutes a contraindication to neuraxial and deep peripheral nerve blocks ...

Saura O, Levy D, Schmidt M

To provide an updated overview of hemostatic disturbances and anticoagulation management during extracorporeal membrane oxygenation (ECMO), emphasizing the mechanisms underlying the dual risk of bleeding and thrombosis, current therapeutic strategies, and future perspectives.Bleeding and thrombot...

Becher EL, Porter SA, Eaton MP, Chabtini L, Cohen Z

Heparin-induced thrombocytopenia (HIT) is a serious concern in cardiac surgery, as heparin use in the at-risk patient can lead to devastating thrombosis. Management strategies for patients with confirmed or suspected HIT include using alternative anticoagulants, such as bivalirudin, but heparin a...

Daniels Z, Walczak AB, Lloyd EA, Wright LK, Nandi D, Deitemyer M et al.

Unfractionated heparin has long been the conventional anticoagulant for pediatric mechanical circulatory support (MCS). As bivalirudin has gained traction in ventricular assist devices (VAD) management, its role in extracorporeal membrane oxygenation (ECMO) is less well defined. We conducted a re...

Unic-Stojanovic D, Vukovic P, Ilic I, Stojicic MM, Tanaskovic S, Kangrga N et al.

Extracorporeal membrane oxygenation (ECMO) is a continuously evolving and increasingly utilized life-support therapy. ECMO requires systemic anticoagulation, which exposes patients to an increased risk of heparin-induced thrombocytopenia (HIT). Clinical experience with alternative anticoagulants ...

Gramegna M, Stegmann A, Pieri M, Nersesian G, Carbone L, Ott S et al.

Hemocompatibility adverse events are frequent in critically ill patients on microaxial flow pump (mAFP) support. Promising experience has accumulated on the use of primary direct thrombin inhibitor (DTI) for anticoagulation in temporary mechanical circulatory support (tMCS). The aim of the study ...

Liang M, Wu P, Zhao Z, Li Y, Ye X, Cui C et al.

The instant blood-mediated inflammatory reaction (IBMIR) is a major barrier to successful intraportal islet engraftment. Bivalirudin, a direct thrombin inhibitor, could mitigate IBMIR by suppressing thrombin activity and platelet activation, yet its role in islet transplantation remains insuffici...

Landi A, Zito A, Singh M, Angiolillo DJ, Capodanno D, Frigoli E et al.

A contemporary, comprehensive risk score for the prediction of in-hospital fatal and nonfatal adverse events after percutaneous coronary intervention has been recently developed, albeit its external validation in patients with acute coronary syndrome is lacking. The objective of this study is to ...

Okabe Y, Rodriguez JI, Edmunds J, Dhliwayo NL

Factor V Leiden (FVL) and the prothrombin 20210A gene mutation are two common genetic predispositions to hypercoagulability. We present a complex case of recurrent venous thromboembolism (VTE) in a 50-year-old woman with double heterozygosity for FVL and prothrombin G20210A, complicated by hepari...

Lofy T, Juul J, Duewell B, Tchen S, Held-Godgluck B, Brazauskas R et al.

Extracorporeal membrane oxygenation (ECMO), a form of temporary mechanical circulatory support, causes a prothrombotic state due to activation of inflammatory processes via exposure of blood to the circuit. Systemic anticoagulation is recommended to prevent thrombosis. Unfractionated heparin (UFH...

Labarinas S, Norbisrath K, Nnaemeka I, Bai Y, Tint H, Johnson D et al.

Extracorporeal membrane oxygenation (ECMO) is a last resort treatment for children with cardio-respiratory failure. Some of these patients will develop thrombocytopenia-associated multiple organ failure (TAMOF), which is sometimes managed with therapeutic plasma exchange (TPE). Our objective is t...